English

Boston Therapeutics, Inc.

EDGAR

BTHE Annual report (10-K) · filed 2023-04-07

59 filing records in this dataset, filed from 2010-02-08 to 2023-04-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q4 · USD

Exact inputs and evidence

Revenue: 15450 USD Source
Revenue: 15450 USD Source

Operating cash flow

-1.8 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -6085990 USD Source
Operating Cash Flow: -4286663 USD Source

Free cash flow

-1.8 million USD

2022 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -6085990 USD Source
Operating Cash Flow: -4286663 USD Source
Capital Expenditure: 26592 USD Source
Capital Expenditure: 23581 USD Source

Cash and cash equivalents: 297 thousand USD 2021-12-31 Source
Exact value

297351 USD
Long-term debt including current maturities: 791 thousand USD 2022-12-31 Source
Exact value

790555 USD
Shares outstanding: 48.8 million shares 2022-12-31 Source
Exact value

48783763 shares

Reported share-count change

820.43% · 43.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

5300084 shares · 2021-12-31· Source
48783763 shares · 2022-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

15.5 thousand USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Revenue: 0 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 15450 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 15450 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 15450 USD · 2022-01-01 – 2022-06-30 Source
Revenue: 15450 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 15450 USD · 2022-01-01 – 2022-09-30 Source

Operating cash flow

-6.09 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -1363753 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -2603824 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -1363753 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -4286663 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -2603824 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -6085990 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -4286663 USD · 2022-01-01 – 2022-09-30 Source

Capital expenditure

26.6 thousand USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Capital expenditure: 22637 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 23581 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 26592 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 23581 USD · 2022-01-01 – 2022-09-30 Source

Free cash flow

-6.11 million USD

2022-01-01 – 2022-12-31

Exact inputs and evidence

Operating cash flow: -1363753 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -2603824 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -1363753 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -4286663 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -2603824 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -6085990 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -4286663 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 23581 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 22637 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 26592 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 23581 USD · 2022-01-01 – 2022-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-04-07.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2022-12-31
Operating income: 11 of 11 periods available· newest 2022-12-31
Net income: 9 of 11 periods available· newest 2020-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
Capital expenditure: 7 of 11 periods available· newest 2022-12-31
Total assets: 11 of 11 periods available· newest 2022-12-31
Total liabilities: 11 of 11 periods available· newest 2022-12-31
Current assets: 11 of 11 periods available· newest 2022-12-31
Current liabilities: 11 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2022-12-31
Shares outstanding: 11 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-89.1%

Prior period

USD 141,778

2021-01-01 – 2021-12-31
Current period

USD 15,450

2022-01-01 – 2022-12-31

Exact inputs and evidence

15450 − 141778 = -126328 USD

141778 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
15450 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Year-over-year change in Revenue: -126328 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 15450 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#1009744 Filing: 000121390023028171 Input fundies:Revenue: 141778 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#1010186 Filing: 000121390023028171
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 231,599

Prior period

−USD 6.32 million

2021-01-01 – 2021-12-31
Current period

−USD 6.09 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-6085990 − -6317589 = 231599 USD

-6317589 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-6085990 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Year-over-year change in Operating cash flow: 231599 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -6085990 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909149 Filing: 000121390023028171 Input fundies:OperatingCashFlow: -6317589 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909612 Filing: 000121390023028171
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-92.1%

Prior period

USD 336,157

2021-01-01 – 2021-12-31
Current period

USD 26,592

2022-01-01 – 2022-12-31

Exact inputs and evidence

26592 − 336157 = -309565 USD

336157 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
26592 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Year-over-year change in Capital expenditure: -309565 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 26592 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#911910 Filing: 000121390023028171 Input fundies:CapitalExpenditure: 336157 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#912347 Filing: 000121390023028171
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 15,450 100% of revenue
Operating costs Derived USD 8.45 million 54,710% of revenue
Operating income −USD 8.44 million −54,610% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −USD 6.09 million −39,392% of revenue
Capital expenditure USD 26,592 172% of revenue
Free cash flow Derived −USD 6.11 million −39,564% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 1,516% of revenue.
2014 Operating loss: operating costs were 2,442% of revenue.
2015 Operating loss: operating costs were 2,224% of revenue.
2016 Operating loss: operating costs were 1,378% of revenue.
2017 Operating loss: operating costs were 4,411% of revenue.
2018 Operating loss: operating costs were 10,438% of revenue.
2019 Operating loss: operating costs were 23,741% of revenue.
2020 Operating loss: operating costs were 1,056% of revenue.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	323412	4903657 Derived	-4580245	-3096130 Derived	-1484115	-2350317 Derived	Source 2013-01-01 – 2013-12-31: 323412 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -4580245 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -1484115 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -2339398 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 10919 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	199582	4873929 Derived	-4674347	25592 Derived	-4699939	-3480650 Derived	Source 2014-01-01 – 2014-12-31: 199582 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -4674347 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -4699939 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -3474140 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 6510 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	98941	2200228 Derived	-2101287	388527 Derived	-2489814	Unavailable	Source 2015-01-01 – 2015-12-31: 98941 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -2101287 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -2489814 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -1294950 USD Inspect Operating Cash Flow Open source
2016 2016-01-01 – 2016-12-31	98878	1362832 Derived	-1263954	2473570 Derived	-3737524	Unavailable	Source 2016-01-01 – 2016-12-31: 98878 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -1263954 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -3737524 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -1249624 USD Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	29356	1295012 Derived	-1265656	319217 Derived	-1584873	-1279906 Derived	Source 2017-01-01 – 2017-12-31: 29356 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -1265656 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -1584873 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -1275202 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4704 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	31723	3311134 Derived	-3279411	321806 Derived	-3601217	Unavailable	Source 2018-01-01 – 2018-12-31: 31723 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -3279411 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -3601217 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -883841 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	16329	3876745 Derived	-3860416	-166337 Derived	-3694079	Unavailable	Source 2019-01-01 – 2019-12-31: 16329 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -3860416 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -3694079 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -1195938 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	513244	5419604 Derived	-4906360	-3998477 Derived	-907883	-3959490 Derived	Source 2020-01-01 – 2020-12-31: 513244 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -4906360 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -907883 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -3916069 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 43421 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	141778	5866929 Derived	-5725151	Unavailable	Unavailable	-6653746 Derived	Source 2021-01-01 – 2021-12-31: 141778 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -5725151 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -6317589 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 336157 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	15450	8452618 Derived	-8437168	Unavailable	Unavailable	-6112582 Derived	Source 2022-01-01 – 2022-12-31: 15450 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -8437168 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -6085990 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 26592 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 15.5K 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	323412	Revenue: 323412 Open source
20142014-12-31	Revenue	199582	Revenue: 199582 Open source
20152015-12-31	Revenue	98941	Revenue: 98941 Open source
20162016-12-31	Revenue	98878	Revenue: 98878 Open source
20172017-12-31	Revenue	29356	Revenue: 29356 Open source
20182018-12-31	Revenue	31723	Revenue: 31723 Open source
20192019-12-31	Revenue	16329	Revenue: 16329 Open source
20202020-12-31	Revenue	513244	Revenue: 513244 Open source
20212021-12-31	Revenue	141778	Revenue: 141778 Open source
20222022-12-31	Revenue	15450	Revenue: 15450 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-89.1% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	665.4%	Revenue: 323412 Open source Revenue: 42254 Open source
20142014-12-31	Year over year	-38.3%	Revenue: 199582 Open source Revenue: 323412 Open source
20152015-12-31	Year over year	-50.4%	Revenue: 98941 Open source Revenue: 199582 Open source
20162016-12-31	Year over year	-0.1%	Revenue: 98878 Open source Revenue: 98941 Open source
20172017-12-31	Year over year	-70.3%	Revenue: 29356 Open source Revenue: 98878 Open source
20182018-12-31	Year over year	8.1%	Revenue: 31723 Open source Revenue: 29356 Open source
20192019-12-31	Year over year	-48.5%	Revenue: 16329 Open source Revenue: 31723 Open source
20202020-12-31	Year over year	3,043.1%	Revenue: 513244 Open source Revenue: 16329 Open source
20212021-12-31	Year over year	-72.4%	Revenue: 141778 Open source Revenue: 513244 Open source
20222022-12-31	Year over year	-89.1%	Revenue: 15450 Open source Revenue: 141778 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -54,609.5% 2022

Net margin -176.9% 2020

Free cash flow margin -39,563.6% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-1,416.2%	Operating Income: -4580245 Open source Revenue: 323412 Open source
20142014-12-31	Operating margin	-2,342.1%	Operating Income: -4674347 Open source Revenue: 199582 Open source
20152015-12-31	Operating margin	-2,123.8%	Operating Income: -2101287 Open source Revenue: 98941 Open source
20162016-12-31	Operating margin	-1,278.3%	Operating Income: -1263954 Open source Revenue: 98878 Open source
20172017-12-31	Operating margin	-4,311.4%	Operating Income: -1265656 Open source Revenue: 29356 Open source
20182018-12-31	Operating margin	-10,337.6%	Operating Income: -3279411 Open source Revenue: 31723 Open source
20192019-12-31	Operating margin	-23,641.5%	Operating Income: -3860416 Open source Revenue: 16329 Open source
20202020-12-31	Operating margin	-956%	Operating Income: -4906360 Open source Revenue: 513244 Open source
20212021-12-31	Operating margin	-4,038.1%	Operating Income: -5725151 Open source Revenue: 141778 Open source
20222022-12-31	Operating margin	-54,609.5%	Operating Income: -8437168 Open source Revenue: 15450 Open source
20132013-12-31	Net margin	-458.9%	Net Income: -1484115 Open source Revenue: 323412 Open source
20142014-12-31	Net margin	-2,354.9%	Net Income: -4699939 Open source Revenue: 199582 Open source
20152015-12-31	Net margin	-2,516.5%	Net Income: -2489814 Open source Revenue: 98941 Open source
20162016-12-31	Net margin	-3,779.9%	Net Income: -3737524 Open source Revenue: 98878 Open source
20172017-12-31	Net margin	-5,398.8%	Net Income: -1584873 Open source Revenue: 29356 Open source
20182018-12-31	Net margin	-11,352.1%	Net Income: -3601217 Open source Revenue: 31723 Open source
20192019-12-31	Net margin	-22,622.8%	Net Income: -3694079 Open source Revenue: 16329 Open source
20202020-12-31	Net margin	-176.9%	Net Income: -907883 Open source Revenue: 513244 Open source
2021-12-31	Net margin	Not reported	Revenue: 141778 Open source
2022-12-31	Net margin	Not reported	Revenue: 15450 Open source
20132013-12-31	Free cash flow margin	-726.7%	Revenue: 323412 Open source Operating Cash Flow: -2339398 Open source Capital Expenditure: 10919 Open source
20142014-12-31	Free cash flow margin	-1,744%	Revenue: 199582 Open source Operating Cash Flow: -3474140 Open source Capital Expenditure: 6510 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 98941 Open source Operating Cash Flow: -1294950 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 98878 Open source Operating Cash Flow: -1249624 Open source
20172017-12-31	Free cash flow margin	-4,359.9%	Revenue: 29356 Open source Operating Cash Flow: -1275202 Open source Capital Expenditure: 4704 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 31723 Open source Operating Cash Flow: -883841 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 16329 Open source Operating Cash Flow: -1195938 Open source
20202020-12-31	Free cash flow margin	-771.5%	Revenue: 513244 Open source Operating Cash Flow: -3916069 Open source Capital Expenditure: 43421 Open source
20212021-12-31	Free cash flow margin	-4,693.1%	Revenue: 141778 Open source Operating Cash Flow: -6317589 Open source Capital Expenditure: 336157 Open source
20222022-12-31	Free cash flow margin	-39,563.6%	Revenue: 15450 Open source Operating Cash Flow: -6085990 Open source Capital Expenditure: 26592 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -6.1M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	-2339398	Operating Cash Flow: -2339398 Open source
20142014-12-31	Operating cash flow	-3474140	Operating Cash Flow: -3474140 Open source
20152015-12-31	Operating cash flow	-1294950	Operating Cash Flow: -1294950 Open source
20162016-12-31	Operating cash flow	-1249624	Operating Cash Flow: -1249624 Open source
20172017-12-31	Operating cash flow	-1275202	Operating Cash Flow: -1275202 Open source
20182018-12-31	Operating cash flow	-883841	Operating Cash Flow: -883841 Open source
20192019-12-31	Operating cash flow	-1195938	Operating Cash Flow: -1195938 Open source
20202020-12-31	Operating cash flow	-3916069	Operating Cash Flow: -3916069 Open source
20212021-12-31	Operating cash flow	-6317589	Operating Cash Flow: -6317589 Open source
20222022-12-31	Operating cash flow	-6085990	Operating Cash Flow: -6085990 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -6.1M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	-2350317	Operating Cash Flow: -2339398 Open source Capital Expenditure: 10919 Open source
20142014-12-31	Free cash flow	-3480650	Operating Cash Flow: -3474140 Open source Capital Expenditure: 6510 Open source
20152015-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1294950 Open source
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1249624 Open source
20172017-12-31	Free cash flow	-1279906	Operating Cash Flow: -1275202 Open source Capital Expenditure: 4704 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -883841 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1195938 Open source
20202020-12-31	Free cash flow	-3959490	Operating Cash Flow: -3916069 Open source Capital Expenditure: 43421 Open source
20212021-12-31	Free cash flow	-6653746	Operating Cash Flow: -6317589 Open source Capital Expenditure: 336157 Open source
20222022-12-31	Free cash flow	-6112582	Operating Cash Flow: -6085990 Open source Capital Expenditure: 26592 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

1,442% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Liabilities / assets	26.2%	Total Liabilities: 1189762 Open source Total Assets: 4535032 Open source
20142014-12-31	Liabilities / assets	93.6%	Total Liabilities: 1088459 Open source Total Assets: 1163122 Open source
20152015-12-31	Liabilities / assets	160.4%	Total Liabilities: 1408575 Open source Total Assets: 878034 Open source
20162016-12-31	Liabilities / assets	322%	Total Liabilities: 4523812 Open source Total Assets: 1404952 Open source
20172017-12-31	Liabilities / assets	529.8%	Total Liabilities: 4787160 Open source Total Assets: 903580 Open source
20182018-12-31	Liabilities / assets	388.1%	Total Liabilities: 5585216 Open source Total Assets: 1439299 Open source
20192019-12-31	Liabilities / assets	32,362.2%	Total Liabilities: 7696051 Open source Total Assets: 23781 Open source
20202020-12-31	Liabilities / assets	2,461.2%	Total Liabilities: 13055976 Open source Total Assets: 530471 Open source
20212021-12-31	Liabilities / assets	766.4%	Total Liabilities: 6941163 Open source Total Assets: 905712 Open source
20222022-12-31	Liabilities / assets	1,442%	Total Liabilities: 14161216 Open source Total Assets: 982055 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.02× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	4.21×	Current Assets: 3751520 Open source Current Liabilities: 891942 Open source
20142014-12-31	Current assets / current liabilities	0.56×	Current Assets: 444655 Open source Current Liabilities: 790639 Open source
20152015-12-31	Current assets / current liabilities	0.22×	Current Assets: 229102 Open source Current Liabilities: 1037578 Open source
20162016-12-31	Current assets / current liabilities	0.77×	Current Assets: 830022 Open source Current Liabilities: 1076861 Open source
20172017-12-31	Current assets / current liabilities	0.11×	Current Assets: 390947 Open source Current Liabilities: 3687960 Open source
20182018-12-31	Current assets / current liabilities	0.2×	Current Assets: 921955 Open source Current Liabilities: 4659410 Open source
20192019-12-31	Current assets / current liabilities	0×	Current Assets: 23272 Open source Current Liabilities: 7696051 Open source
20202020-12-31	Current assets / current liabilities	0.05×	Current Assets: 172794 Open source Current Liabilities: 3736822 Open source
20212021-12-31	Current assets / current liabilities	0.14×	Current Assets: 468839 Open source Current Liabilities: 3325098 Open source
20222022-12-31	Current assets / current liabilities	0.02×	Current Assets: 80138 Open source Current Liabilities: 4049755 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 1.48 million Exact value Exact value: -1484115 USD 2013-01-01 – 2013-12-31: -1484115 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2013-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -1484115 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1484115 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262415000441/bthe-20141231.xml#37002 Filing: 000110262415000441 The citation records this snapshot. The page link may show a newer release later.	−USD 2.34 million Exact value Exact value: -2339398 USD 2013-01-01 – 2013-12-31: -2339398 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2013-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -2339398 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2339398 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262415000441/bthe-20141231.xml#56898 Filing: 000110262415000441 The citation records this snapshot. The page link may show a newer release later.	USD 10,919 Exact value Exact value: 10919 USD 2013-01-01 – 2013-12-31: 10919 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2013-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 10919 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10919 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262415000441/bthe-20141231.xml#58303 Filing: 000110262415000441 The citation records this snapshot. The page link may show a newer release later.	−USD 2.35 million Calculation and evidence -2339398 − 10919 USD Exact free cash flow: -2350317 USD 2013-01-01 – 2013-12-31: -2339398 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 10919 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2013-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -2350317 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2339398 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262415000441/bthe-20141231.xml#56898 Filing: 000110262415000441 Input fundies:CapitalExpenditure: 10919 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262415000441/bthe-20141231.xml#58303 Filing: 000110262415000441 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 4.7 million Exact value Exact value: -4699939 USD 2014-01-01 – 2014-12-31: -4699939 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2014-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -4699939 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4699939 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262416002414/bthe-20151231.xml#122449 Filing: 000110262416002414 The citation records this snapshot. The page link may show a newer release later.	−USD 3.47 million Exact value Exact value: -3474140 USD 2014-01-01 – 2014-12-31: -3474140 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2014-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -3474140 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3474140 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262416002414/bthe-20151231.xml#61456 Filing: 000110262416002414 The citation records this snapshot. The page link may show a newer release later.	USD 6,510 Exact value Exact value: 6510 USD 2014-01-01 – 2014-12-31: 6510 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2014-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 6510 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6510 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262416002414/bthe-20151231.xml#61769 Filing: 000110262416002414 The citation records this snapshot. The page link may show a newer release later.	−USD 3.48 million Calculation and evidence -3474140 − 6510 USD Exact free cash flow: -3480650 USD 2014-01-01 – 2014-12-31: -3474140 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 6510 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2014-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -3480650 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3474140 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262416002414/bthe-20151231.xml#61456 Filing: 000110262416002414 Input fundies:CapitalExpenditure: 6510 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000110262416002414/bthe-20151231.xml#61769 Filing: 000110262416002414 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 2.49 million Exact value Exact value: -2489814 USD 2015-01-01 – 2015-12-31: -2489814 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2015-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -2489814 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2489814 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577417001275/bthi-20161231.xml#238170 Filing: 000161577417001275 The citation records this snapshot. The page link may show a newer release later.	−USD 1.29 million Exact value Exact value: -1294950 USD 2015-01-01 – 2015-12-31: -1294950 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2015-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -1294950 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1294950 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577417001275/bthi-20161231.xml#245619 Filing: 000161577417001275 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2016 2016-01-01 – 2016-12-31	−USD 3.74 million Exact value Exact value: -3737524 USD 2016-01-01 – 2016-12-31: -3737524 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2016-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -3737524 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3737524 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577418002112/bthe-20171231.xml#164393 Filing: 000161577418002112 The citation records this snapshot. The page link may show a newer release later.	−USD 1.25 million Exact value Exact value: -1249624 USD 2016-01-01 – 2016-12-31: -1249624 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2016-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -1249624 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1249624 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577418002112/bthe-20171231.xml#185823 Filing: 000161577418002112 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 1.58 million Exact value Exact value: -1584873 USD 2017-01-01 – 2017-12-31: -1584873 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2017-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -1584873 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1584873 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577419005825/bthe-20181231.xml#339774 Filing: 000161577419005825 The citation records this snapshot. The page link may show a newer release later.	−USD 1.28 million Exact value Exact value: -1275202 USD 2017-01-01 – 2017-12-31: -1275202 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2017-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -1275202 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1275202 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577419005825/bthe-20181231.xml#171152 Filing: 000161577419005825 The citation records this snapshot. The page link may show a newer release later.	USD 4,704 Exact value Exact value: 4704 USD 2017-01-01 – 2017-12-31: 4704 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2017-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 4704 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4704 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577419005825/bthe-20181231.xml#347599 Filing: 000161577419005825 The citation records this snapshot. The page link may show a newer release later.	−USD 1.28 million Calculation and evidence -1275202 − 4704 USD Exact free cash flow: -1279906 USD 2017-01-01 – 2017-12-31: -1275202 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4704 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2017-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -1279906 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1275202 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577419005825/bthe-20181231.xml#171152 Filing: 000161577419005825 Input fundies:CapitalExpenditure: 4704 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000161577419005825/bthe-20181231.xml#347599 Filing: 000161577419005825 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 3.6 million Exact value Exact value: -3601217 USD 2018-01-01 – 2018-12-31: -3601217 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2018-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -3601217 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3601217 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390020014377/bthe-20191231.xml#336758 Filing: 000121390020014377 The citation records this snapshot. The page link may show a newer release later.	−USD 883,841 Exact value Exact value: -883841 USD 2018-01-01 – 2018-12-31: -883841 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2018-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -883841 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -883841 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390020014377/bthe-20191231.xml#633762 Filing: 000121390020014377 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 3.69 million Exact value Exact value: -3694079 USD 2019-01-01 – 2019-12-31: -3694079 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2019-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -3694079 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3694079 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390021022666/bthe-20201231.xml#160899 Filing: 000121390021022666 The citation records this snapshot. The page link may show a newer release later.	−USD 1.2 million Exact value Exact value: -1195938 USD 2019-01-01 – 2019-12-31: -1195938 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2019-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -1195938 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1195938 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390021022666/bthe-20201231.xml#168019 Filing: 000121390021022666 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 907,883 Exact value Exact value: -907883 USD 2020-01-01 – 2020-12-31: -907883 USD Inspect Net Income Open source Share or cite Citation for Net Income · Boston Therapeutics, Inc. · 2020-12-31 Boston Therapeutics, Inc. (edgar:1473579) Net Income: -907883 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -907883 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390021022666/bthe-20201231.xml#162413 Filing: 000121390021022666 The citation records this snapshot. The page link may show a newer release later.	−USD 3.92 million Exact value Exact value: -3916069 USD 2020-01-01 – 2020-12-31: -3916069 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2020-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -3916069 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3916069 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390022019462/f10k2021_nanomixcorp.htm#908199 Filing: 000121390022019462 The citation records this snapshot. The page link may show a newer release later.	USD 43,421 Exact value Exact value: 43421 USD 2020-01-01 – 2020-12-31: 43421 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2020-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 43421 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 43421 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390022019462/f10k2021_nanomixcorp.htm#909950 Filing: 000121390022019462 The citation records this snapshot. The page link may show a newer release later.	−USD 3.96 million Calculation and evidence -3916069 − 43421 USD Exact free cash flow: -3959490 USD 2020-01-01 – 2020-12-31: -3916069 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 43421 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2020-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -3959490 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3916069 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390022019462/f10k2021_nanomixcorp.htm#908199 Filing: 000121390022019462 Input fundies:CapitalExpenditure: 43421 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390022019462/f10k2021_nanomixcorp.htm#909950 Filing: 000121390022019462 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−USD 6.32 million Exact value Exact value: -6317589 USD 2021-01-01 – 2021-12-31: -6317589 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2021-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -6317589 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6317589 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909612 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.	USD 336,157 Exact value Exact value: 336157 USD 2021-01-01 – 2021-12-31: 336157 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2021-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 336157 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 336157 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#912347 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.	−USD 6.65 million Calculation and evidence -6317589 − 336157 USD Exact free cash flow: -6653746 USD 2021-01-01 – 2021-12-31: -6317589 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 336157 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2021-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -6653746 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6317589 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909612 Filing: 000121390023028171 Input fundies:CapitalExpenditure: 336157 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#912347 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−USD 6.09 million Exact value Exact value: -6085990 USD 2022-01-01 – 2022-12-31: -6085990 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Operating Cash Flow: -6085990 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6085990 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909149 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.	USD 26,592 Exact value Exact value: 26592 USD 2022-01-01 – 2022-12-31: 26592 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Capital Expenditure: 26592 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26592 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#911910 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.	−USD 6.11 million Calculation and evidence -6085990 − 26592 USD Exact free cash flow: -6112582 USD 2022-01-01 – 2022-12-31: -6085990 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 26592 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Boston Therapeutics, Inc. · 2022-12-31 Boston Therapeutics, Inc. (edgar:1473579) Free cash flow: -6112582 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-03T22:32:21Z Snapshot: c9946b13e7f9bf1b0dc68cadaee6a57b7cb2949bb9335aea95daf9dc5baf3fb3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1473579?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -6085990 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#909149 Filing: 000121390023028171 Input fundies:CapitalExpenditure: 26592 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1473579/000121390023028171/f10k2022_nanomixcorp.htm#911910 Filing: 000121390023028171 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

59 filings · 2,947 latest values · 2,940 originally reported values

Dataset published 2026-11-03. Source filing dates and reporting periods are shown separately.

Identifiers: 0001473579, 1473579, BTHE, NNMX, edgar:1473579

Also known as AVANYX Therapeutics, Inc., BOSTON THERAPEUTICS, inc., Boston Therapeutics, Inc., NANOMIX CORPORATION, NANOMIX Corp

Boston Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation